AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $218.24 million. The enterprise value is $130.36 million.
| Market Cap | 218.24M |
| Enterprise Value | 130.36M |
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 99.20 million shares outstanding. The number of shares has increased by 0.43% in one year.
| Current Share Class | 99.20M |
| Shares Outstanding | 99.20M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | -2.37% |
| Owned by Insiders (%) | 5.72% |
| Owned by Institutions (%) | 5.48% |
| Float | 38.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.29 |
| Forward PS | 6.21 |
| PB Ratio | 5.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 28.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 0.14.
| Current Ratio | 0.87 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -318.22 |
Financial Efficiency
Return on equity (ROE) is -104.83% and return on invested capital (ROIC) is -59.16%.
| Return on Equity (ROE) | -104.83% |
| Return on Assets (ROA) | -23.06% |
| Return on Invested Capital (ROIC) | -59.16% |
| Return on Capital Employed (ROCE) | -142.30% |
| Weighted Average Cost of Capital (WACC) | 12.66% |
| Revenue Per Employee | $37,830 |
| Profits Per Employee | -$676,680 |
| Employee Count | 122 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.80% in the last 52 weeks. The beta is 1.57, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | +6.80% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 2.97 |
| Relative Strength Index (RSI) | 38.26 |
| Average Volume (20 Days) | 276,005 |
Short Selling Information
The latest short interest is 3.38 million, so 6.92% of the outstanding shares have been sold short.
| Short Interest | 3.38M |
| Short Previous Month | 3.52M |
| Short % of Shares Out | 6.92% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.54 |
Income Statement
In the last 12 months, AC Immune had revenue of $4.62 million and -$82.55 million in losses. Loss per share was -$0.82.
| Revenue | 4.62M |
| Gross Profit | -60.54M |
| Operating Income | -80.14M |
| Pretax Income | -82.55M |
| Net Income | -82.55M |
| EBITDA | -78.42M |
| EBIT | -80.14M |
| Loss Per Share | -$0.82 |
Balance Sheet
The company has $93.25 million in cash and $5.37 million in debt, with a net cash position of $87.88 million or $0.89 per share.
| Cash & Cash Equivalents | 93.25M |
| Total Debt | 5.37M |
| Net Cash | 87.88M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 39.31M |
| Book Value Per Share | 0.40 |
| Working Capital | -15.20M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.71M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,736.39% |
| Pretax Margin | -1,788.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | -37.83% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AC Immune is $8.51, which is 286.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.51 |
| Price Target Difference | 286.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 207.94% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -5.09. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.09 |
| Piotroski F-Score | n/a |